Head-To-Head Survey: Bullfrog AI (NASDAQ:BFRG) versus Chemomab Therapeutics (NASDAQ:CMMB)

Bullfrog AI (NASDAQ:BFRG) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Earnings & Valuation

This table compares Bullfrog AI and Chemomab Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$60,000.00	329.53	-$5.36 million	($0.85)	-2.67
Chemomab Therapeutics	N/A	N/A	-$24.22 million	($1.14)	-1.53

Bullfrog AI has higher revenue and earnings than Chemomab Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Bullfrog AI has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Bullfrog AI and Chemomab Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0	0	0	0	0.00
Chemomab Therapeutics	0	0	3	1	3.25

Chemomab Therapeutics has a consensus price target of $5.67, indicating a potential upside of 225.67%. Given Chemomab Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Bullfrog AI.

Profitability

This table compares Bullfrog AI and Chemomab Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-141.39%	-124.63%
Chemomab Therapeutics	N/A	-102.80%	-76.79%

Insider & Institutional Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 33.9% of Bullfrog AI shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Chemomab Therapeutics beats Bullfrog AI on 9 of the 13 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.